

05/30/00 05-31-00 A/BOX SEQ

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))</small>	Attorney Docket Number	97-489-US-P
	First Inventor or Application Identifier	SANDBERG et al.
	Title	USES FOR ELASTIN PEPTIDE ANALOGS
	Express Mail Label No.	EM269452218US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>	ADDRESS TO: Commissioner for Patents Box Patent Application Washington, DC 20231
--	--


1. <input type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original, and a duplicate for fee processing)</small>	5. <input type="checkbox"/> Microfiche Computer Program (Appendix)
2. <input checked="" type="checkbox"/> Specification [Total Pages 55] <small>(preferred arrangement set forth below)</small> -Descriptive title of the invention -Cross References to Related Applications -Statement Regarding Fed sponsored R & D -Reference to Microfiche Appendix -Background of the invention -Brief Summary of the invention -Brief Description of the Drawings (if filed) -Detailed Description -Claim(s) -Abstract of the Disclosure	6. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small> a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies

3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets 3]	ACCOMPANYING APPLICATION PARTS 7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 8. <input type="checkbox"/> 37 CFR § 3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small> 9. <input type="checkbox"/> English Translation Document (if applicable) 10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 11. <input type="checkbox"/> Preliminary Amendment 12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 13. <input type="checkbox"/> *Small Entity <input type="checkbox"/> Statement filed in prior application, Status still proper and desired 14. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 15. <input checked="" type="checkbox"/> Other: Express Mail Label #EM269452218US
4. <input type="checkbox"/> Oath or Declaration [Total Pages]	
a. <input type="checkbox"/> Newly executed (original or copy)	
b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 16 completed)</small> i. <input type="checkbox"/> DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) named in the prior application, see §§ 37 CFR §1.63(d)(2) and 1.33(b)</small>	
c. <input type="checkbox"/> Unsigned	

NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27); EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment:
☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No. 09/039,308
Prior application information: Examiner M. Borin Group/Art Unit: 1654
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

17. CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number or Bar Code Label <small>(Insert Customer No. or Attach bar code label here)</small> or <input checked="" type="checkbox"/> Correspondence address below					
NAME	Raymond A. Miller Reed Smith Shaw & McClay LLP				
ADDRESS	P.O. Box 488				
CITY	Pittsburgh	STATE	PA	ZIP CODE	15230-0488
COUNTRY	US	TELEPHONE	412-288-4192	FAX	412-288-3300

Name (Print/Type)	Raymond A. Miller	Registration No. (Attorney/Agent)	42,891
Signature		Date	May 30, 2000


Certificate of Mailing by "Express Mail"

JC714 U.S. PTO
09/580156
05/30/00

EM269452218US
"Express Mail" label number

May 30, 2000
Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service on the date indicated above and is addressed to the Box Patent Application, Commissioner for Patents, Washington, D.C. 20231.



Signature of person mailing correspondence

Jody L. Burtner
Typed or printed name of person mailing correspondence

Note: Each paper must have its own certificate of mailing by "Express Mail".

ELASTIN PEPTIDE ANALOGS AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATION

This application claims continuing status pursuant to 35
5 U.S.C. § 120 to U.S. Application No. 09/039,308 filed March 13, 1998, and
to International Application No. PCT/US99/05496 filed March 12, 1999.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to compositions which are
10 particularly suitable as therapeutics, pharmaceuticals, and/or cosmetics.
The compositions of the present invention preferably include a peptide or
peptide-like compound which simulate the effect of elastin. Preferably,
compounds of the present invention are substantially homologous or
analogous with a portion of mammalian elastin, even more preferably
15 with fragments of elastin endogenous to the tissue of the mammal being
treated. It is preferable that the peptide or peptide-like compound(s) of
the present invention are at a therapeutically effective concentration
and/or are an active ingredient of a pharmaceutical, therapeutic and/or
cosmetic composition. The peptide or peptide-like compound(s) of the
20 present invention appear to aid the elasticity and/or turgor of the skin.
Another aspect of the present invention is a method of administering the
compositions of the present invention to achieve a therapeutic,
pharmaceutical, or cosmetic effect.

2. Background and Description of the Related Art

25 Elastin, a highly cross-linked complex polypeptide, is a major
component of elastic fibers present in the tissue of animals. Elastin is
found in most connective tissues in conjunction with collagen and

polysaccharides. Relatively large amounts of elastin are also found in the walls of blood vessels, particularly in the arch of the aorta near the heart, as well as in ligaments. Elastin is present in lesser amounts in skin, tendons, and loose connective tissue. In normal mammalian skin,
 5 specifically human skin, elastic tissue proteins represent a relatively small fraction of the total dermal proteins, but play a very important role in maintaining the tone, structure, and turgor of the skin.

Elastin fibers are capable of stretching to several times their length and then rapidly returning to their original size upon release of
 10 tension. Hence, elastin contributes to the physiological elasticity of tissue. It has been found, for instance, that a loss of elasticity in the skin is associated with decrease in the tone and turgor of the skin. It is speculated that the decrease in skin tone and turgor occurs through degradation of elastin and collagen. Attempts have been made to use
 15 elastin as a cosmetic agent, however, the dense cross-linked structure of elastin makes it very difficult to solubilize. In fact, elastin is only slightly absorbed by the skin and does not penetrate the skin sufficiently to produce substantial benefits. Attempts to solubilize elastin and create cosmetic agents are described, for example, in U.S. Patent No. 4,327,078.

20 SUMMARY OF THE PRESENT INVENTION

The present invention is directed to compositions which are pharmaceutical, therapeutic, and/or cosmetic in nature. The composition of the present invention preferably modifies or appears to modify the physical characteristics of the tissue to which it is applied. The
 25 composition generally includes a vehicle or carrier for therapeutic, pharmaceutical, or cosmetic administration in which the peptide or peptides are formulated.

The compound(s) which best accomplish an increase or apparent increase in tissue elasticity and turgor are ones which
 30 correspond to, are analogous to, or are substantially homologous, with portions of elastin. As used herein, the terms "peptide" or "peptide-like" is

not meant to convey any meaning regarding the precursor material or methods utilized to make the compounds. For instance, compounds or compositions contemplated within the present invention are those that mimic the action or functionality of the amino acid containing peptides or peptide-like compounds of the present invention. Computational chemistry can be used to predict structure-function relationship, and compounds thus predicted and synthesized may mimic the structure and function of a particular peptide or peptide-like compound disclosed herein. Additionally, the term "elastin peptide fragment" in either singular or plural form refers to the fact that the peptide or amino acid sequence being discussed: corresponds to; is the biological equivalent of; is analogous with; or is substantially homologous with, a portion of elastin. The term "elastin peptide fragment" is not meant to convey any meaning regarding the source or starting material or method of arriving at the elastin peptide fragment.

It is preferable that the peptides of the present invention are formulated at an effective concentration within the therapeutic, pharmaceutical or cosmetic composition. The therapeutically effective concentration is preferably in a range of about .0002% to about 90% by weight of the peptide or peptide-like compound, more preferably in a range of about .05% to about 50% peptide, even more preferably in a range of about 0.5% to about 10% peptide, and even more preferably about 1.5% peptide. The therapeutic composition of the present invention can be formulated as a cosmetic preparation to be applied topically to a patient's skin, such as in an emulsion, lotion, spray, powder, ointment, cream, or foam or in other suitable pharmaceutical vehicles or carriers commonly known in the art for other types of administration (*e.g.*, oral or subcutaneous). The delivery system of the present invention is preferably a topical delivery system but also may be a subcutaneous, transcutaneous, oral, nasal, aerosol, or patch. The peptide(s) or peptide-like compound(s) of the present invention have many other applications, for example they may also be used to coat surgical devices such as stents and the like.

The present invention is also directed to a method of enhancing the functionality, tone, turgor, and/or elasticity of the tissue to which it is administered by administering effective amounts of a peptide to the tissue. When treating skin, the appearance of the skin is enhanced.

- 5 It is believed that this enhancement is a consequence of improving the elasticity of the skin. It is preferable that the administration step be comprised of a number of separate steps which are repeated over a predetermined time (*e.g.*, twice daily). It is preferable that the predetermined time exceeds one week of daily administration of the
- 10 compound, more preferably two weeks, and most preferably at least a month of daily topical application (with twice daily of the peptide administration over the month being even more preferable).

- One embodiment of the present invention is directed to peptide having a formula of R_1 -Valyl-Valyl-Prolyl- R_2 , wherein R_1 is an
- 15 amino portion modified to include an amine, amide, or amino acid sequence having 1-10 amino acids and R_2 is a carboxy portion modified to include an amide, ester, or carboxy terminus sequence having 1-10 amino acids.

- Another embodiment of the present invention is directed to
- 20 peptide having a formula of R_1 -Leucine-Glycine- R_2 , wherein R_1 is an amino portion modified to include an amine, amide, or amino acid sequence having 1-10 amino acids and R_2 is a carboxy portion modified to include an amide, ester, or carboxy terminus sequence having 1-10 amino acids.

- 25 Another embodiment of the present invention is directed to peptide having a formula of R_1 -Leucine-Glycine-Alanine-Glycine-Glycine-Alanine-Glycine- R_2 , wherein R_1 is an amino portion modified to include an amine, amide, or amino acid sequence having 1-10 amino acids and R_2 is a carboxy portion modified to include an amide, ester, or carboxy terminus
- 30 sequence having 1-10 amino acids.

The present invention is also directed to a composition being comprised of a peptide selected from the group consisting of SEQ ID 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, SEQ ID 5, SEQ ID 6, SEQ ID 7, SEQ ID 8, SEQ ID 9, SEQ ID 10, SEQ ID 11, SEQ ID 12, SEQ ID 13, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 17, SEQ ID 18, SEQ ID 19, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 23, SEQ ID 24, SEQ ID 25, SEQ ID 26, SEQ ID 27, SEQ ID 28, SEQ ID 29, SEQ ID 30, SEQ ID 31, SEQ ID 32, SEQ ID 33, SEQ ID 34, SEQ ID 35, SEQ ID 36, SEQ ID 37, SEQ ID 38, SEQ ID 39, SEQ ID 40, SEQ ID 41, SEQ ID 42, SEQ ID 43, SEQ ID 44, SEQ ID 45, SEQ ID 46, SEQ ID 47, SEQ ID 48, SEQ ID 49, SEQ ID 50, SEQ ID 51, SEQ ID 52, SEQ ID 53, SEQ ID 54 and their biological equivalents.

The peptides or peptide-like compounds of the present invention may be utilized to affect gene expression. An embodiment of the present invention therefore includes a method for regulating gene expression (e.g. in fibroblasts) comprising applying a composition containing a peptide or a peptide-like compound to cells. This composition may contain peptides selected from the group consisting of SEQ IDs 1-75; and are preferably SEQ ID 17 and/or SEQ ID 19. The gene expression regulated may include processes selected from the group of signaling cascades, DNA synthesis, DNA repair, apoptosis, cell to cell communication and similar such processes.

Further, the composition of the invention and their biological equivalents may be suitable as a therapeutic, pharmaceutical or cosmetic to enhance elastin production and may also be used to treat a variety of diseases or conditions. These diseases or conditions can be selected from the group consisting of conditions or diseases of the skin, tendons, sheaths and/or bone, hair, lip, back or spine, brain or nervous system, autoimmune system, lungs, muscle, joints, nails, blood vessels/lymphatics, breast, cartilage, ear, eye, genito-urinary tract, gastrointestinal tract, immunologic systems, ulcerative, blood vessels/heart (e.g., hypertension), and other body systems.

BRIEF DESCRIPTION OF THE DRAWINGS

The features, aspects, and advantages of the present invention will become better understood in light of the following description, appended claims, and accompanying drawings wherein:

5 Fig. 1 is a bar graph illustrating increased elastin production as a result of application of select compounds of the present invention to mammalian skin.

 Fig. 2 is a micrograph illustrating the microvascular response of the skin tissue with peptides of the present invention.

10 Fig. 3 is a bar graph illustrating tritiated Thymidine incorporation with selected peptide or peptide-like compounds.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

15 So that the invention described herein may be more fully understood, the following detailed description is set forth. The description is in no way meant to limit the breadth of the claims, but rather to specifically point out novel aspects of the present invention.

20 The present invention relates to compositions which are useful in increasing functionality, elasticity, tone, turgor, and/or appearance of tissue. The present invention is also directed to administering therapeutically effective concentrations of the compositions.

 As used herein, the term "subject" or "patient" means any mammal, including humans, in which elastin is utilized for proper tissue function or appearance. The methods herein for use contemplate prophylactic, cosmetic, and curative use.

25 As used herein, the term "about" means plus or minus 10% of the numerical value of the number with which it is being used. Therefore,

about 50% means in the range of 45%-55%. As used herein, the term "Dalton" (or "Da") refers to the unit of mass which is equivalent to the mass of a hydrogen atom (1.66×10^{-24} gram). Generally speaking, the term "tissue" refers to any aggregation of similarly specialized cells which are united in the performance of a particular function. The term "tissue", as usually used herein, refers to tissue which includes elastin as part of its preferred structure and/or function. For example, connective tissue which is made up of, among other things, collagen fibrils and elastin fibrils satisfies the definition of "tissue". Additionally, since elastin appears to be inherently involved in the visco-elasticity of blood vessels, veins, and arteries, these would be encompassed in the definition of "tissue". The term "skin" is encompassed by the term "tissue" but specifically means the outer integument or covering of the body, including the dermis and the epidermis which rests upon subcutaneous tissue.

"Providing" when used in conjunction with a therapeutic, pharmaceutical, or cosmetic means to administer an agent directly into or onto a target tissue or to administer a therapeutic to a patient whereby the therapeutic positively impacts the tissue to which it is targeted (either in a prophylactic, curative or cosmetic manner). Thus, as used herein, the term "providing", when used in conjunction with elastin peptide fragment, can include, but is not limited to, providing an elastin peptide fragment into or onto the target tissue; providing an elastin peptide fragment systemically to a patient by, *e.g.*, intravenous injection whereby the therapeutic agent reaches the target tissue; providing an elastin peptide fragment in the form of the encoding sequence thereof to the target tissue (*e.g.*, by so-called gene-therapy techniques) whereby the elastin peptide fragment is expressed within the target tissue. Details on techniques for formulation and administration of pharmaceuticals may be found in the latest edition of Remington's Pharmaceutical Sciences (Mack Publishing Co, Easton Pa.). Although local topical delivery is desirable, there are other acceptable means of delivery, for example: oral, parenteral, aerosol, intramuscular, subcutaneous, transcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.

As used herein, the term "therapeutic" means an agent utilized to treat, combat, ameliorate, prevent or improve a condition or disease of a patient. A particular condition treated in the present invention is deficient elastin in a particular tissue, that is, a need in the tissue for more elastin. As it applies to skin, "therapy" is often measured by turgor, tone, appearance, degree of wrinkles, and youthfulness. As the term applies to blood vessels it may be measured by the degree of elasticity or proper vasomotor response (vasodilatation/vasoconstriction) of the vessel. Accordingly, therapeutic treatment of blood vessels may have implications in diseases associated with visco-elasticity, including hypertension, arteriosclerosis, angina, angiogenesis, myocardial infarction, coronary thrombosis, restenosis post angioplasty, and chronic obstructive pulmonary disease.

Finally, the term "cosmetic," as used herein, refers to a beautifying substance or preparation which preserves, restores, bestows, simulates, or enhances the appearance of bodily beauty, specifically as it relates to the appearance of tissue or skin.

The compounds and compositions of the present invention may also be useful as an agent for modifying tissue, especially skin. The term "modify" is used to convey that the present invention changes either the appearance, form, characteristics and/or the physical attributes of the tissue to which it is being provided, applied or administered. The change in form can be reflected in any of the following alone or in combination: enhanced appearance of the skin; increased softness of the skin; increased turgor of the skin; increased texture of the skin; increased elasticity of the skin; decreased wrinkle formation and increased endogenous elastin production in the skin.

Elastin can be used as starting material in the digestion or cleavage methods described herein. This elastin can be derived from a number of sources known in the art. The sequences of the present invention can either be isolated from the digestion pool (and chemically modified if desired) or the peptides may be synthesized with a peptide

sequencer. A particularly useful source of elastin is *ligamentum nuchae*. *Ligamentum nuchae* contains large amounts of elastin (approximately 70% of the dry weight of this ligament is elastin), especially in proportion to the amount of collagen. Due to the relatively high elastin content and relatively low collagen content, *ligamentum nuchae* is an ideal starting material to use in deriving the elastin peptide fragments of the present invention. The *ligamentum nuchae* may be cleaned first using a procedure similar to that disclosed in U.S. Patent No. 5,028,695, the cleaning portion of which is incorporated herein by reference thereto.

Although a preferred source of starting elastin is *ligamentum nuchae*, other ligaments, tendons, connective tissue, tissue, and synthetic sources may also be used. For example, the arteries and lungs, and other animal tissue, especially those which have significant amounts of elastin, can be used (e.g., rat, sheep, and porcine aorta can be used as a source of elastin as described in L.B. Sandberg, *Connective Tissue Research*, 1990, Vol. 25, pp. 139-148, incorporated herein in its entirety by reference thereto). Also, elastin from different sources, or elastin and collagen from the same or different sources could be mixed together to produce a particular advantageous mix suitable for digestion or hydrolytic cleavage.

In one embodiment of the present invention, the ligament extraction process is comprised of taking dissected *ligamentum nuchae* ligaments and removing as much fat and excess connective tissue as possible. These "clean" ligaments are then chopped into about one centimeter square (1 cm²) pieces and washed with doubly distilled water ("DDW"). The clean ligaments are then placed on a metal mortar, pre-chilled to -20°F and liquid nitrogen is added to freeze the tissue. The ligaments are then minced or pulverized with the appropriate tool and re-suspended in 1% aqueous NaCl at a ratio of about 100 grams of tissue to about three liters of 1% aqueous NaCl and homogenized in a Waring blender at high speed for 30-60 seconds. The homogenized ligament is transferred to a four-liter beaker and stirred overnight at 4°C on a magnetic stirrer, after which it is centrifuged at 32,500 x G and the supernatant is checked for protein content using the Biuret method for protein determination. The Biuret reaction is done by mixing 2 milliliters

of extract with 3 milliliters of reagent and reading immediately either by simple visual inspection or at 540 nanometers on a spectrophotometer to determine the protein concentration of the supernatant. The supernatant is then discarded. The pellet (referred to hereinafter as the elastin pellet) is resuspended in 1% aqueous NaCl and homogenized. The process of homogenizing in a Waring blender, stirring overnight and centrifuging are repeated three to four times until the supernatant is Biuret negative. After centrifugation, the elastin pellet is resuspended in DDW and autoclaved 30 psi for six hours. The resuspended elastin pellet is centrifuged again and the supernatant is tested for protein content via the Biuret method. The elastin is washed with boiling DDW and then with DDW at room temperature and the washes are tested for protein content via the Biuret method. If the washes are Biuret negative, the elastin pellet is dried with chloroform/methanol solution at a ratio of 2 parts chloroform to 1 part methanol. If the Biuret test is positive, the six hour autoclave procedure with wash step is repeated until the Biuret test is negative. Finally, the elastin residue is washed with five volumes of pure methanol and air-dried at room temperature. The elastin residue is transferred to a desiccator and dried over P_2O_5 for 24 hours until the weight of the elastin residue is stable. The elastin residue is then milled in a Willey mill through a 40-mesh screen followed by a 60-mesh screen.

For the thermolysin digestion, three times re-crystallized thermolysin product from CalBiochem (10394 Pacific Center Court, San Diego, CA 92121) was used. The thermolysin preparation contains sufficient calcium to ensure maximal activity of the enzyme. The thermolysin digestion is done as follows: a waterbath is brought to a 55° C temperature with a rotary shaker and five grams of the finely milled largely insoluble elastin residue is hydrated with one liter of DDW for fifteen minutes at room temperature. After hydration, the one liter DDW which contains the five grams of elastin is placed in the 55° C bath and the pH of the elastin/water mixture is brought to a pH between 7-8 with 10% methylamine. Fifty milligrams of thermolysin (*bacillus thermoproteolyticus*) is added directly to the elastin water mixture. The thermolysin contains about 60% protein (60.2%), about 13% (13.2%)

sodium acetate, and about 25% (25.3%) calcium acetate, with a specific activity of about 8,720 I.U./mg dry weight. The pH of the elastin water mixture is monitored with a pH meter or pH stat and adjusted with 10% methylamine to keep the pH between 6.8 and 7.5. The digestion is
 5 allowed to continue for 75 minutes and then concentrated hydrochloric acid is added to adjust the pH to 3.0 to terminate the digestion.

After digestion is terminated, the digested product is preferably filtered through a PM 10 Diaflow 10,000 molecular weight cut-off ultra-filtration membrane to filter out any protein or peptides
 10 exceeding about 10,000 Da molecular weight. The resulting supernatant is a derived composition comprised of peptides having a molecular weight of less than about 10,000 Da.

Table I is a list of peptide sequences (originally isolated in the supernatant) which, either alone or in combination, in exhibit
 15 desirable characteristics.

TABLE I

SEQ #	PEPTIDE	MOL WT	NAME (N- to C-terminal)
1.	AVG	245	Alanine-Valine-Glycine
2.	VGAG	302	Valine-Glycine-Alanine-Glycine
3.	IGG	302	Isoleucine-Glycine-Glycine
4.	LG	188	Leucine-Glycine
5.	IGAG	316	Isoleucine-Glycine-Alanine-Glycine
6.	LGG	245	Leucine-Glycine-Glycine
7.	VAPG	342	Valine-Alanine-Proline-Glycine
8.	LGPG	342	Leucine-Glycine-Proline-Glycine
9.	LGAG	316	Leucine-Glycine-Alanine-Glycine
10.	VGPG	328	Valine-Glycine-Proline-Glycine
11.	FGPG	376	Phenylalanine-Glycine-Proline-Glycine

SEQ #	PEPTIDE	MOL WT	NAME (N- to C-terminal)
12.	VGPQ	399	Valine-Glycine-Proline-Glutamine
13.	LGA	259	Leucine-Glycine-Alanine
14.	VGPA	342	Valine-Glycine-Proline-Alanine
15.	VVPG	370	Valine-Valine-Proline-Glycine
16.	AVPG	342	Alanine-Valine-Proline-Glycine
17.	VVPQ	441	Valine-Valine-Proline-Glutamine
18.	VAARPG	569	Valine-Alanine-Alanine-Arginine-Proline-Glycine
19.	LGAGGAG	501	Leucine-Glycine-Alanine-Glycine-Glycine-Alanine-Glycine
20.	AIPG	356	Alanine-Isoleucine-Proline-Glycine
21.	LGPGG	399	Leucine-Glycine-Proline-Glycine-Glycine
22.	AAAQA	430	Alanine-Alanine-Alanine-Glutamine-Alanine
23.	VGVDypG	444	Valine-Glycine-Valine-Hydroxyproline-Glycine
24.	VYPGG	491	Valine-Tyrosine-Proline-Glycine-Glycine
25.	IGGVGG	458	Isoleucine-Glycine-Glycine-Valine-Glycine-Glycine
26.	VAPGVG	498	Valine-Alanine-Proline-Glycine-Valine-Glycine
27.	LGVGG	401	Leucine-Glycine-Valine-Glycine-Glycine
28.	VLPG	384	Valine-Leucine-Proline-Glycine
29.	FRAAA	534	Phenylalanine-Arginine-Alanine-Alanine-Alanine
30.	VGGVPG	484	Valine-Glycine-Glycine-Valine-Proline-Glycine
31.	FGPGG	433	Phenylalanine-Glycine-Proline-Glycine-Glycine
32.	VGVP	427	Valine-Glycine-Valine-Proline-Glycine
33.	VLPGAG	512	Valine-Leucine-Proline-Glycine-Alanine-Glycine
34.	VGLHypG	458	Valine-Glycine-Leucine-Hydroxyproline-Glycine
35.	LGVGA	415	Leucine-Glycine-Valine-Glycine-Alanine
36.	AFPG	390	Alanine-Phenylalanine-Proline-Glycine
37.	AFPGA	461	Alanine-Phenylalanine-Proline-Glycine-Alanine
38.	VGIPA	455	Valine-Glycine-Isoleucine-Proline-Alanine
39.	VGGIPT	542	Valine-Glycine-Glycine-Isoleucine-Proline-Threonine

SEQ #	PEPTIDE	MOL WT	NAME (N- to C-terminal)
40.	VGVGVP	583	Valine-Glycine-Valine-Glycine-Valine-Proline-Glycine
41.	LGPGVG	498	Leucine-Glycine-Proline-Glycine-Valine-Glycine

* SEQ IDs 23 and 32 appear to be a common sequence because Proline hydroxylation is a post-translational event.

The elastin peptide fragment/water mixture (inclusive of
5 SEQ IDs 1-41) which is obtained upon digestion with thermolysin described
above is flash evaporated to dryness and redissolved in a small volume of
DDW and if desired is diluted sufficiently with DDW for lyophilization to
dryness. In the alternative, rather than redissolving the elastin peptide(s),
the filtered product is freeze dried twice, resulting in a powder which
10 contains 30 weight chemically-bound water and very little salt (NaCl).

The method of administering peptides and formulations of the
present invention employs any of a number of known administrative routes
such as oral, IV, subcutaneous, transcutaneous, and topical administration.
A preferred method of the present invention employs a pharmaceutical or
15 cosmetic composition which enhances the physical appearance of and/or the
elasticity of tissue. Compositions of the present invention may be in the form
of a peptide or peptides in combination with at least one other agent, such as
stabilizing compound, which may be administered in any sterile, bio-
compatible pharmaceutical carrier, including, but not limited to, saline,
20 buffered saline, dextrose, and water. The compositions may be administered
to a patient alone, or in combination with other agents, drugs or hormones.
Pharmaceutically-acceptable carriers may also be comprised of excipients and
auxiliaries which facilitate processing of the active compounds into
preparations which can be used pharmaceutically. Further details on
25 techniques for formulation and administration may be found in the latest
edition of Remington's Pharmaceutical Sciences. The pharmaceutical
composition may be provided as a salt and can be formed with many acids,
including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric,
malic, succinic, etc. Salts tend to be more soluble in aqueous or other

protonic solvents than are the corresponding free base forms. After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.

A typical cream incorporating SEQ IDs 1-41 of the present invention is described as follows in order of relative concentration of each of the ingredients: Purified Water, Hydrolyzed elastin peptides ("HEP") (i.e. SEQ IDs 1-41), Polyglycerylmethacrylate (and) propylene glycol, Petrolatum, Dicaprylylether, Peg- 5, Glycerylstearate, Glycerine, Dimethicone (and) dimethiconal, Cetyl alcohol, Sweet almond oil, Acrylates/C10-30, Tocotheryl acetate, Phenoxyethynol, Benzyl alcohol, Disodium EDTA, Sodium hydroxide, Lactic acid, Sodium chloride.

It is believed that one of the advantages of the present invention is the apparent ability of the peptides or peptide-like compounds of the present invention to penetrate the skin. Advantageously, the present invention uses peptides which have a molecular weight of less than about 10,000 Da, more preferably less than about 3,000 Da, even more preferably less than 1,000 Da. Thus, the peptides of the present invention would appear to meet many of the criteria for absorption by the skin upon application.

The present invention can be formulated in a number of carrier vehicles, for example, in a spray; an aerosol; a water and an oil-type emulsion; an oil and water-type emulsion; a face cream or body cream; a sun lotion or after-sun lotion; or other topical administration vehicle. U.S. Patent No. 4,327,078, which was referenced earlier, is illustrative of the different types of topical administrations which may be employed to administer a soluble elastin-based derivative, and is incorporated herein by reference for this purpose.

The peptide or peptides (as described herein SEQ IDs 1-54), and their biological equivalents, of the present invention, as well as their corresponding compositions are expected to have a variety of important

applications. The following descriptions provide a brief summary of the conditions these peptide(s) are expected to benefit.

Skin conditions: There are many skin conditions and diseases which would benefit from elastin treatment. Beyond the obvious cosmetic applications (*i.e.*, increased tone, turgor, and appearance), enhanced elastin production will produce long-term beneficial results. For example, the inherited disease Scleroderma is characterized by a thickening and stiffening of the skin, and cutaneous ulcers due to the overproduction of collagen (there are a number of diseases which involve overproduction of collagen and which seem to have an adverse effect on elastin production/content and compromise the tissue). This disease can also have systemic effects on organs and blood vessels. The stiffness and difficulty in motion along with the cutaneous ulcers would benefit greatly from incorporation of elastin into the skin. A similarly positive outcome would be expected with the treatment of lupus and rheumatoid related skin changes which are generally collagen-vascular diseases involving a decrease in elastin.

Other skin conditions would appear to benefit from the present invention. Conditions and problems such as acne rosacea, acne vulgaris, aging skin with vascular fragility, burn treatment, scar contractures from burns, radiation burns, pruritis (or chronic itching), psoriasis, urticaria (commonly referred to as hives), xerosis (abnormal dryness of the skin, eyes or mouth), vesicular dermatoses, cracked fingers and feet, drug eruptions (from an allergic reaction), epidermolysis (a skin condition where the epidermis is in a loosened state, often with the formation of blebs and bullae either spontaneously or after trauma), and erythema multiforme would benefit from treatment with the elastin peptide(s) of the present invention.

Additionally, there are heritable skin disorders such as cutis laxa and EDS or Ehlers Danlos Syndrome (a group of connective tissue disorders in which the skin hangs in loose pendulous folds believed to be caused by decreased elastic tissue formation as well as an abnormality in elastin formation or an excess of collagen), EDS, elastoderma, progeria, and pseudoxanthoma elasticum (an inherited disorder in which elastic fibers

found in many tissues slowly become calcified) which would benefit from an increase in elastin in the affected tissues.

It is believed that the application of the elastin peptides of the present invention would result in an increase in tissue elastin and may
5 provide effective treatment for serious diseases such as pemphigus.

Tendons, Sheaths and Bone: Tendons, sheaths and bone all are comprised in part of elastin. Chronic, painful conditions affecting some of these tissues include carpal tunnel disease, fasciitis, flat feet, and tendonitis. These conditions and similar ones will be improved with increased levels of
10 elastin in the affected tissue. Bone spurs, fascial tears, ligament tears and tendon tears will heal faster with supplemental elastin provided by the elastin peptides of the present invention. These tissues may even become stronger as a result of the expected stimulation of elastin production accompanying this treatment. Additionally, cartilage growth abnormalities
15 may be corrected by application of elastin peptides of the present invention.

Treatment with the elastin peptides of the present invention will also be useful in veterinary medicine for skin ulcerations in livestock such as horses and cattle. Hoof problems can be very painful and problematic for horses and other hoofed animals. Hoof conditions would
20 benefit from increased elastin levels which could be provided and induced by treatment with elastin peptides of the present invention.

Hair: Hair growth, color, and removal can all be improved by treatment with elastin peptides which will make the hair stronger, more shiny, and improve the condition and healing of irritated skin upon removal
25 of unwanted hair. Premature graying of hair may also be due to decreased elastin.

Lips: Chapped lips and chronic dermatitis or inflammation of the lips can be greatly improved upon treatment with elastin peptides of the present invention. Long-term relief would be a potential benefit from the
30 stimulation of endogenous elastin in these tissues.

Back: The breakdown of elastin in the spine can contribute to herniated disks and lead to acute and/or chronic pain. Replacing elastin with peptides of the present invention along with the stimulation of endogenous elastin could result in improved healing of the disk and reduce or eliminate the pain associated with this condition, especially when combined with other treatments, such as steroids.

Brain and nervous system: In nerve compression syndromes, treatment with elastin peptides of the present invention will likely stimulate endogenous elastin production in certain neurological conditions and promote revascularization after stroke and neural tissue transplants. This revascularization could greatly improve the clinical outcome of these treatments.

Autoimmune diseases: Lupus and other rheumatoid related diseases are characterized by localized destruction or degeneration of elastin in tissues throughout the body. These and similar diseases could greatly benefit from treatment with elastin peptides of the present invention which would promote restoration of damaged tissue and even provide long-term benefit from the stimulation of endogenous elastin.

Lungs: Many lung diseases including chronic obstructive pulmonary disease, laryngeal stenosis, pulmonary fibrosis, pulmonary sarcoid and tracheal stenosis are associated with a decrease in elastin, an important component in maintaining the elasticity and proper functioning of the lung. Often, these lung conditions are due to a decrease in particular proteases which normally balance the activity of elastin-degrading proteases, referred to generally as elastases. An example of this type of deficiency is alpha 1 protease inhibitor deficiency. A decrease in elastin due to this type of deficiency causes a breakdown of the lung matrix which is vital for proper lung function. Other factors, such as smoking can also lead to breakdown of the elastin component of the lung matrix.

Muscle: Muscles are often covered with a thin layer of connective tissue which is comprised of elastin and other components such as collagen. Thus, applying peptides of the present invention to muscle tissue

would increase muscle tone and the healing of muscle tears and generally strengthen muscles by increasing their elastin content.

Joints: Similarly, joints are comprised of connective tissue, including elastin. In many cases individuals suffer from joint pain and joint abnormalities as a result of inflammatory disease or from wear and tear which all generally result in decreased amounts of elastin present in the connective tissue of joints. Thus, many joint diseases or problems such as athletic joint injuries, torn cartilage and/or ligaments, osteoarthritis, joint pain, rheumatoid arthritis, and stiff joints could benefit from treatment with elastin peptides of the present invention. These elastin peptides will have the capability to stimulate endogenous elastin in these tissues and may provide substantial and long-term rebuilding and maintenance of the elastin in these tissues.

Nails: Elastin is useful in treating and preventing nail brittleness, split nails, and to enhance the hardness of nails in general. Nails are comprised of flattened epidermal cells and have a high concentration of elastin in the nail bed. Thus, increasing the elastin content of these cells will result in a stronger and more flexible nail.

Blood vessels/ lymphatics: Elastin is an important constituent of vessels; therefore, application of elastin to affected tissues in vascular diseases which involve abnormalities of arteries or veins including atherosclerotic occlusive disease, chronic venous insufficiency, diabetic vasculitis (inflammation of a vessel caused by diabetes), fibrotic mediastinitis associated with superior vena cava syndrome (an exuberant inflammatory sclerogenic process of infectious, rheumatic, hemorrhagic, or undetermined origin, often accompanied by obstruction of mediastinal structure, especially the vena cava), varicose veins, temporal arteritis, stasis dermatitis, and lymphedema (including elephantiasis, which is a chronic unilateral or bilateral edema of the extremities due to accumulation of interstitial fluid as a result of the stasis of lymph, which is caused by an obstruction of the lymph vessels).

Breast: Capsule contractures secondary to breast implants are disorders of fibers and are conditions of fixed high resistance (rigidity) to passive stretch of a muscle. Fibrocystic disease, selected cases of breast cancer where there is tissue loss may also benefit from treatment with elastin peptides.

Cartilage growth: Transformation of hyaline cartilage to elastin cartilage in remaking of structures such as an ear, nose, larynx or any structure in which elastic cartilage would be beneficial, could be aided by treatment with elastin peptides.

Ear: Chronic serous otitis media and hearing loss secondary to otitis media as well as other diseases causing scarring of the ear drum can benefit from replacement of elastin which can serve to repair scarred ear drum tissue caused by these chronic infections.

Eye: Eye disorders such as diabetic retinitis, retinal hemorrhages associated with pseudoxanthoma elasticum (PXE), macular degeneration, and retinitis pigmentosa all involve abnormalities of the retina which is comprised in part of elastic fibers. PXE is an inherited disorder in which elastic fibers become slowly calcified, producing characteristic changes in the skin, the retina of the eye, and the cardiovascular system. Incorporation of healthy, normal elastin peptides to the retinas of individuals affected by these disorders could improve vision and lead to healing of the retina and prevention of further damage caused by the lack of or presence of malformed elastin in this tissue.

Genito-urinary tract: There are various genito-urinary conditions which are associated with either chronic inflammation or other condition leading to a decrease in elasticity of connective tissue, or with the narrowing of canals or ducts (strictures). The replenishing of elastin or the reversal of the strictures by treatment with elastin and the stimulation of endogenous elastin would benefit a number of genito-urinary conditions including benign prostatic hyperplasia, chronic sclerosing vaginitis, glomerular sclerosis, ureteral stricture, urethral stricture and use with urethral stents, uterine benign fibroids, and vaginal stenosis.

Gastrointestinal tract: A number of GI conditions are the result of chronic inflammation, or abnormal thickening or calcification of GI tissues including anal fissures, chronic pancreatitis, esophageal stenosis, esophageal varicies, hemorrhoids, intestinal adhesions, and pyloric stenosis. Crohn's disease as well as other localized inflammatory/fibrotic bowel diseases are characterized by a chronic granulomatous inflammatory condition of unknown etiology. Scarring and thickening of the bowel wall frequently leads to intestinal obstruction and the formation of fistula and abscesses. It is likely that supplying elastin to these tissues may improve gastrointestinal function in these patients and restore the normal balance of connective tissue components in the gastrointestinal tract. Similarly, in biliary cirrhosis and fibrotic liver diseases such as liver cirrhosis, diffuse and interlacing bands of fibrous tissue form and replace the normal liver lobules.

Immunology: Enhancement of the immune response through cytokine activation as well as suppression of immunity for prevention of transplant rejection and for treatment of autoimmune disorders may be mediated by altering elastin levels. It has been shown that human activated lymphocytes express the elastin-laminin receptor. The expression of the elastin-laminin receptor is a general property of most activated human lymphocytes, but is dependent upon lymphocyte subsets. Elastin peptides activate these receptors and trigger the stimulation of biosynthesis and release of an elastase.

Ulcerations: Ulcers are defects or excavations of the surface of an organ or tissue, produced by the sloughing of inflammatory tissue. Common ulcerative disorders include esophageal, duodenal, and gastric ulcers. It is believed that providing ulcerative tissues with elastin will speed the healing of the affected tissue and possibly even strengthen the tissue by stimulating endogenous elastin production.

Blood Vessels/Heart: Since large amounts of elastin are found in the walls of blood vessels, particularly in the arch of the aorta near the heart, it is important to maintain the normal healthy balance of elastin in blood vessels and other vessels (such as lymph vessels). Additionally, in pulmonary tissues, the subendothelium is comprised of the internal elastic

lamina, a layer which normally separates the endothelium from the underlying smooth muscle cells. In many cardiac diseases such as congestive heart failure, coronary artery disease, homocystinuria, restrictive pericarditis, sclerosing endocarditis, supra ventricular aortic stenosis, this internal elastic lamina is compromised due to the breakdown of elastin resulting in a remodeling of this matrix layer. This breakdown is often the result of an imbalance in enzyme(s) (such as elastase) which degrade elastin. In some cases, such as in Marfan's syndrome, the elastin malformations are due to an autosomal dominant, congenital disorder affecting connective tissue. Thus, providing affected tissue with normal elastin peptides may be a useful treatment for strengthening the connective tissue in individuals with Marfan's syndrome.

A bacterial infection caused by the group A beta hemolytic Streptococci resulting in rheumatic fever can sometimes lead to rheumatic heart disease, a serious condition characterized by inflammation, and degeneration of connective tissue structures of the body, especially of the heart valves. Treatment of tissues affected by rheumatic heart disease with elastin peptides may allow these tissues to heal and be rebuilt. Additional clinical uses of supplemental elastin peptides include as arterial stents to enhance internal elastic membrane regeneration in angioplasty procedures.

Hypertension: High arterial blood pressure (generally hypertension) can be the result of multiple and diverse etiologies including congenital heart defects, chronic lung disease, hepatic disorders, and autoimmune disease (particularly scleroderma). Hypertension is often marked by endothelial perturbations as well as abnormalities in the subendothelium. These subendothelial problems are manifested in the breakdown of the internal elastic lamina, often by an enzyme which degrades elastin. This breakdown results in the remodeling or rearrangement of the laminar matrix which may result in chronic hypertension. Correcting the elastin composition of the internal elastic lamina with supplemental elastin peptides would improve this condition and would likely augment the standard treatment which includes elastase inhibiting drugs.

With blood vessel and hypertension, a particularly suitable use of the peptides of the present invention would be along with a stent. Depending on the nature of the stent, the stent may have the therapeutic mixture (*e.g.*, peptide(s) alone or in combination with other therapeutic uses) incorporated in the body of the stent or coated thereon. For incorporation, normally a biodegradable plastic stent will be used which will release the therapeutic agents while supporting the vessel and protecting against restenosis. In the fabrication of the stent, the biodegradable matrix may be formed by any convenient means known in the art. Alternatively, the stent may be coated with the therapeutic mixture, using an adhesive or coating which will allow for controlled release of the therapeutic mixture. The stent may be dipped, sprayed or otherwise coated with a composition containing the NO precursor agent or the therapeutic mixture and a matrix, such as biodegradable polymers, a physiologically acceptable adhesive, proteins, polysaccharides or the like. By appropriate choice of the material for the stent and/or the coating comprising the therapeutic mixture, a physiologically active amount of the therapeutic mixture may be maintained at the site of the vascular injury, usually at least one day and up to a week or more.

With the aforementioned wide-spread applicability in mind, a number of peptide or peptide-like compounds were isolated and/or synthesized and analyzed for their suitability as therapeutic, pharmaceutical, or cosmetic agents.

As can be seen from Fig. 1, the topical treatment with a composition which included peptide fragments (*i.e.*, SEQ IDs 1-41) at a concentration of about 1.3% (wt/wt) of the formulation when applied to the skin of a Sprague-Dawley male rat over a one month period illustrates a doubling of the elastin content of the skin, as compared to both control samples and similar applications and concentration of DHEA. In Figure 1, S CONTR represents the Shaven Control and US CONTR represents the Unshaven Control. Fig. 1 illustrates that the compounds of the present invention have the advantageous qualities of enhancing the softness or elasticity of the skin. The peptides and formulations of the present invention also appear to improve the texture of skin, specifically the physical appearance of the skin.

In the Sprague-Dawley rats used to generate Fig. 1, the rats were treated topically with a 1.3% concentration (wt/wt) of the preparation of the hydrophilic elastin peptide for a period of 30 days. Testing illustrated that the endogenous elastin (measured by microgram (μ g) Elastin per milligram (mg) Skin Fat Free Dry weight) of each of the rats to which the composition was applied doubled over that of a control sample and to a sample which was treated with a 5% concentration of DHEA over a similar time period. Three animals each were used to generate the data for S CONTR, US CONTR, and DHEA and eleven animals were used for HEP.

Three skin samples from the treated areas of each animal were taken for study, and the three results from each animal were averaged. The mean of these results were: S CONTR (1.408); US CONTR (2.291); DHEA (1.753); HEP (3.175). The elastin content of the skin was determined by a precise assay for rat elastin developed by Sandberg, et al. (*Connective Tissue Research*. 25: 139-48, 1990) the assay portion of which is hereby incorporated herein by reference thereto. An alpha level less than 0.001 for the data of Fig. 1 as determined by analysis of variance is significant because there is less than one chance in a thousand that the findings occur by chance. The data of Fig. 1 further supports the use of the cosmetic or pharmaceutical preparation over an extended period preferably in the range of one week to one month, more preferably in the range of seven days to about fourteen days and most preferably about fourteen days of daily administration at about 1.5% concentration (wt/wt) of elastin peptide or peptides with concentrate on pharmaceutical preparation..

Fig. 2 is a micrograph illustrating an increased appearance and beneficial implication of the present invention. From Fig. 2, skin treated with an elastin peptide fragment appears to be healthier than untreated skin. This is evidenced under a microscope by an increase in vascular response. In Fig. 2, fixed tissue sections of rat skin were labeled with fluorescein conjugated antifibronectin antibodies. Fig. 2a is a representative sample from the unshaven control tissue; Fig. 2b is a representative sample from the shaven control sample; and Fig. 2c is a representative sample of the tissue which received DHEA topical treatment. Finally, Fig. 2d received treatment with the present invention a topical form in accordance with the samples discussed above with regard to Fig. 1. The dermal layer in the

control panels (Figs. 2a and 2b) is relatively uniform and thin compared to the thickness of both Figs. 2c and 2d. For convenience, in each of panels Figs. 2a - 2 d, the dermal layer is bracketed. Surprisingly, panel Fig. 2d illustrates an increased concentration of capillary venules in the subdermal region. The capillary venules are shown in this figure as brightly stained oval bodies that lie beneath the dermal layer. The increase in the concentration of endothelial cells in the subdermal region indicates an increase in capillary density and therefore illustrates the potential for the peptides and formulations of the present invention to be used for the formation of blood vessels or capillary venules (neovascularization or angiogenesis).

As can be seen from Table II below, it would appear that certain groups of the peptides described in Table I have preferred characteristics as they relate to cosmetic, pharmaceutical or therapeutic application to the skin. The elastin peptide mixture isolated from thermolysin digestion of elastin (*i.e.*, SEQ ID 1 - SEQ ID 41 inclusive) was collected as they came off of a HPLC column. Instead of isolating each of the thermolysin peptide fragments individually, 5 fractions or clusters of peptides were collected in the 5-50 minute range and were tested for activity utilizing a bromodeoxyuridine Triphosphate (BrdUTP) incorporation assay. The assay measures production of mRNA involved in protein synthesis. Table II measures the green fluorescence intensity as a measure of increased mRNA in RFL-6 cells in response to the pooled elastin fragment.

TABLE II

<u>Fraction #</u>	<u>Approximate Elution time</u>	<u>Approximate % Change w/Control Subtracted Out</u>
1	5.3 min. - 11.8 min	1%
2	11.8 min - 23.0 min	4%
3	23.0 min - 44.1 min	41%
4	44.1 min - 45.8 min	10%
5	45.8 min - 50.0 min	2%
6	Unfractionalized mixture (SEQ IDs 1-41)	52%

Each of the fractions show an increase in mRNA in RFL-6 cells over the control group. From the test, however, it appears that Fraction #3 alone and/or in combination with other fractions (*e.g.*, as seen with Fraction #6) has a preferred composition when increasing elasticity, turgor, and/or appearance of tissue, specifically skin. Fraction 3 includes SEQ IDs 14-31. It should be noted that in light of the ease in obtaining the unfractionalized mixture (as described above) it may be more preferable to use the unfractionalized mixture than isolating the most active ingredient.

Fraction or Cluster 3 was sub-fractionated into 10 fractions corresponding to the ten major peaks identified on the HPLC (at 215 nm). Table III below illustrates the green fluorescence intensity as a measure of increased mRNA in RFL-6 cells in response to sub-fractionated portions of Fraction No. 3.

TABLE III

<u>Fractionated #</u>	<u>Seq. No. Contained Therein</u>	<u>Abbreviated Peptide Sequence</u>	<u>% Change of Green Fluorescence Intensity</u>
1	SEQ ID 14	VGPA	39
2	SEQ IDs 15, 16	VVPG, AVPG	40
3	SEQ ID 17	VVPQ	85
4	SEQ IDs 18, 19	VAARPG, LGAGGAG	44
5	SEQ IDs 20, 21	AIPG, LGPGG	42
6	SEQ ID 22	AAAQA	20
7	SEQ ID 23	VG ^{VH} ypG	57
8	SEQ ID 24	VYPGG	38
9	SEQ IDs 25, 26, 27, 28, 29	IGGVGG, VAPGVG, LGVGG, VLPG, FRAAA	10
10	SEQ IDs. 30, 31	VGGVPG, FGPGG	23
Blank (Background)			30







As can be clearly seen from Table III, it appears SEQ ID 17 (VVPQ) has the greatest activity, followed by SEQ ID 23 (VGVHypG), SEQ ID 18 (VAARPG), and SEQ ID 19 (LGAGGAG). It would appear that SEQ IDs. 22 and 25-31 actually may adversely impact the overall therapeutic or cosmetic value of Fraction 3. However, applicant does not wish to be bound by this speculation in that any one or combination of these fractions while lowering the green fluorescence intensity of the fractionated sample may in fact add a desirable characteristic to the intended use of the overall mixture or when combined with another peptide (*e.g.*, any of SEQ IDs 1-41 respectively). In other words, other types of testing (*e.g.*, other types of tissue) may in fact demonstrate suitability of other peptides for pharmaceutical and/or cosmetic purposes, even those adversely indicated herein.

Based on the information provided by Table I - Table III, the VVP sequence appears important. SEQ ID 17 (VVPQ), for example, showed particularly good activity. Derivatives of SEQ ID 17 were synthesized. Table IV illustrates the three types of derivatives of SEQ ID 17 which were synthesized and determined to be suitable as pharmaceutic, therapeutic, and or cosmetic compositions in accordance with the present invention.

TABLE IV (VVPQ derived peptides)

SEQ #	PEPTIDE	MOL WT	NAME (N- to C-terminal)
42	VVPQNH ₂	448	Alanine-Valine-Proline-Glutamine-Amide
43	(CH ₃ CO)VVPQ	475	Acetyl-Valine-Valine-Proline-Glutamine
44	(CH ₃ CO)GAVVPQNH ₂	610	Acetyl-Glycine-Alanine-Valine-Valine-Proline-Glutamine-Amide
45	AVVPQ	512	Alanine-Valine-Valine-Proline-Glutamine
46	GAVVPQ	569	Glycine-Alanine-Valine-Valine-Proline-Glutamine
47	AVVPQNH ₂	519	Alanine-Valine-Valine-Proline-Glutamine-amide
48	GAVVPQNH ₂	576	Glycine-Alanine-Valine-Valine-Proline-Glutamine-amide

TABLE IV (VVPQ derived peptides)

SEQ #	PEPTIDE	MOL WT	NAME (N- to C-terminal)
49		647	Cysteine-Valine-Valine-Proline-Glutamine-Cysteine
50		718	Cysteine-Alanine-Valine-Valine-Proline-Glutamine-Cysteine
51		775	Cysteine-Glycine-Alanine-Valine-Valine-Proline-Glutamine-Cysteine
52		64 647	Copper Cysteine-Valine-Valine-Proline-Glutamine-Cysteine
53		64 718	Copper Cysteine-Alanine-Valine-Valine-Proline-Glutamine-Cysteine
54		64 775	Copper Cysteine-Glycine-Alanine-Valine-Valine-Proline-Glutamine-Cysteine

SEQ IDs 45-48 illustrate various modifications of VVPQ at either the amino terminus or carboxy terminus of the peptide, and SEQ IDs 49-54 correspond to cyclic versions of SEQ ID 17. SEQ IDs 49-54 have cysteine residues at each end respectively to allow for formation of a disulfide bridge (*i.e.*, SEQ IDs 49-51) or through a metal chelate (*i.e.*, SEQ IDs 52-54), such as copper.

The bar graph of Fig. 3 illustrated the potential effect of modifying sequences in a variety of ways. The results of modifying SEQ ID 17 (what appears to be the most active peptide for many purposes) provide important information on the impact of such modifications. For instance, the modifications made to SEQ IDs 42 and 43 appear to adversely impact the suitability for these purposes. SEQ ID 4 (LG) resulted in about an 8% CPM above the control; SEQ ID 17 (VVPQ) resulted in about a 28% CPM above the control; SEQ ID 19 (LGAGGAG) resulted in about an 18% CPM above the control; SEQ ID 42 (VVPQ-NH₂) resulted in about a 1% CPM above the control; SEQ ID 43 (Acetyl-VVPQ) resulted in about a 1% CPM above the control; SEQ ID 48 (GAVVPQ--NH₂) resulted in about a 25% CPM above the

control; and SEQ ID 44 (Acetyl-GAVVPQ--NH₂) resulted in about a 5% CPM above the controls. From Fig. 3 and Table VII it appears that the synthetic peptide SEQ ID 17 appears has the same or nearly the same activity as SEQ ID 17 isolated from the HPLC fractionalization. It would also appear
 5 that a GA residue attached to the N-terminus of the SEQ ID 42 (resulting in SEQ ID 48) has a similar activity to the activity of SEQ ID 17. The ubiquity of the GA residue in an elastin's peptide sequence suggests that such a modification of other peptide fragments may augment their activity and/or otherwise may be desirable. Having an amide at the carboxyl terminus or an
 10 acetyl at the N-terminus may also beneficially affect activity and/or solubility of the subject peptide.

The information derived from Table III and Fig. 3 can be utilized to systematically synthesize peptides which would appear to be suitable as pharmaceutical, cosmetic, and/or therapeutic compositions.
 15 A general method for synthesizing the peptides discussed herein is described in U.S. Patent No. 4,816,513, incorporated herein by reference thereto in its entirety, which describes a process for automatically constructing a polypeptide. Additionally, U.S. Patent No. 4,668,476, incorporated herein by reference thereto in its entirety, also describes an apparatus for
 20 automatically constructing a polypeptide and a transfer system to transfer activated species from the activator system to the reaction vessel and to transfer amino acids, reagents, gases and solvents from one part of the apparatus to another. Generally, this synthesis process is conducted using Fmoc chemistry on automated solid phase synthesizers, (or in some cases by
 25 Boc chemistry). In most cases, the synthesized peptides would be purified by HPLC using reversed phase C4 and C18 columns. Alternate purification methods include ion exchange and gel filtration chromatography.

This preliminary data suggests the importance of VVP and VVPQ (*e.g.* see Figs 1-3) as well as LGAGGAG. The peptides VVPQ
 30 (SEQ ID 17) and LGAGGAG (SEQ ID 19) were further analyzed using human skin fibroblasts. These peptides have striking and distinct influences on gene expression patterns of these cultured skin fibroblasts. In one study, human skin fibroblasts were grown to confluency in T75 cell-culture flasks (2 passages) using Dulbecco's modified essential media (DMEM) complemented

with 10% fetal calf serum (FCS), 50 μ l penicillin, 50 μ l streptomycin and 100 μ l neomycin. After removing the media, the cells were washed with 10% phosphate buffered saline (PBS) and media supplemented with either 10 μ g/ml VVPQ or 10 μ g/ml LGAGGAG, respectively. The control culture media
 5 contained no added peptides. The fibroblasts were treated in this manner for 4 hours after seeding. The media was subsequently removed and total RNA was extracted using RNA STAT-60 (Tel-Test, Friendswood, TX).

Fifty micrograms of total RNA from each sample (either VVPQ, LGAGGAG, or control) was treated with DNase I at 37°C for 1 hour in order
 10 to remove possible genomic DNA contamination. This treated total RNA was then size-separated by electrophoresis through a 1.2% denaturing gel to confirm that no significant degradation of RNA had taken place.

Next, 5 μ g of treated total RNA from each cell sample was reverse transcribed to single-stranded cDNA using [α -³²P] dATP and reverse
 15 transcriptase, according to the manufacturer's protocol for the Clontech Atlas array (Palo Alto, CA). Column chromatography of the labeled cDNA probes as well as hybridization to the array membranes was also performed according to the manufacturer's protocol. A Molecular Dynamics
 20 PhosphorImager SI (Sunnyvale, CA) was used to expose and screen the membranes following hybridization and post-hybridization washing.

The array experiments were performed in two sets: 1. untreated fibroblasts and VVPQ - treated fibroblasts, 2. untreated fibroblasts and LGAGGAG - treated fibroblasts. Each set of data was quantitated, compared and analyzed using either Clontech's AtlasImage (Palo Alto, CA) or
 25 Molecular Dynamic's ImageQuant (Sunnyvale, CA) software. A Clontech atlas array (Palo Alto, CA) of 588 cDNAs was utilized to analyze the changes in steady state mRNA levels within all 6 functional cDNA groups using fibroblasts treated and untreated with the elastin peptides VVPQ and LGAGGAG. Autoradiograms of duplicate arrays probed with ³²P-labeled
 30 cDNA obtained from total RNA isolated from VVPQ-treated and untreated skin fibroblasts were analyzed using ImageQuant (Sunnyvale, CA) software.

In the DNA array analysis, the autoradiographic signal obtained from each duplicate cDNA set on each filter is compared to the control cDNAs on the same filter. This intensity ratio is then compared for the same duplicate cDNAs between filters. Increased recovery of signal using a cDNA probe from RNA isolated from treated fibroblasts is interpreted as increased mRNA levels. Decreased mRNA levels are observed as a decrease in signal. There were instances where there were no significant hybridization of labeled cDNA to membrane bound duplicate cDNA spots. All of those array signals that indicated up or down regulation of steady state mRNA levels of at least two-fold in response to VVPQ treatment were identified and are listed in TABLES V and VI.

TABLE V
THE IDENTITY OF mRNAs UP-REGULATED
AS A CONSEQUENCE OF VVPQ TREATMENT

GENE	Ratio
Adenosine A1 receptor (ADORA1)	5
Caspase-10 precurs. (CASP10); ICE-LIKE apoptotic protease 4 (ICE-LAP4); IL-1-beta converting enzyme 2 (FLICE)	2
Activator 1 37-kDa subunit; replication factor C 37-kDa subunit (RFC37); RFC4	2
HHR23A; UV excision repair protein, protein RAD23A	2
Interleukin-2 receptor alpha subunit precursor (IL2RA); p55; TAC antigen; CD25	3

TABLE VI
THE IDENTITY OF mRNAs DOWN-REGULATED
AS A CONSEQUENCE OF VVPQ TREATMENT

GENE	Ratio
Transforming protein rhoA H12 (RHO12; ARH-12; ARHA)	4
27-kDa heat-shock protein (HSP27); stress-responsive protein 27 (SRP27); estrogen-regulated protein; HSPB1	2
mutL protein homolog; DNA mismatch repair protein MLH1; COCA2	2
c-AMP-dependent transcr. factor ATF-4; DNA-bind. Prot. TAXREB67; cAMP- response element binding prot. (CREB2)	2
cyclin-dep. Kinase inhib. (CDKN1A); melanoma differentiation-associated prot. 6 (MDA6); CDK-interact. Prot. 1 (CIP1); WAF1	3
Fibronectin receptor beta subunit (FNRB); integrin beta 1 (ITGB1); VLA4 beta subunit; CD29 antigen	2
Thymosin beta-10 (TMSB10; THYB10); PTMB10	2

The determined identity of proteins encoded by mRNAs either increased or decreased in steady state levels in response to the treatment of skin fibroblasts with the elastin peptide LGAGGAG and this data has been presented in TABLES VII and VIII.

5 The response of skin fibroblasts to these two elastin peptides was different. VVPQ treatment results in an alteration in steady state levels of relatively few mRNAs. Of the five mRNAs upregulated in steady state levels, four encode proteins involved in either apoptosis or DNA repair. These include caspase 10 and RFC4. No particular functional class of
10 mRNAs predominate among the seven mRNAs downregulated in response to VVPQ treatment. It can be hypothesized that to date it appears that VVPQ has a significant influence on apoptosis in these human fibroblast cultures. It may be true that this influence is carried out in a manner that is little or poorly understood at this time. Additionally, the interpretation of VVPQ
15 treatment may be limited by the size and makeup of this particular array.

In contrast to the VVPQ treatment, the peptide LGAGGAG resulted in an increased steady state level of 59 different mRNAs. Of these, 32% (19 of 59 mRNAs) encode proteins involved in either apoptosis or DNA repair. Although the number of mRNAs altered by treatment with
20 LGAGGAG is twelve times greater than with VVPQ, an influence by both peptides on apoptosis and or DNA repair is similar. The larger and distinctly different influence of LGAGGAG, however, appears to be on mRNAs encoding proteins involved in cell to cell communication. Forty percent (24 of 59 cDNAs) of mRNAs increased in levels in response to treatment of fibroblasts
25 with LGAGGAG. These include mRNAs encoding proteins such as endothelin 2, oncostatin, TGF- β and BMP2A. Interestingly, the levels of only four mRNAs were noted to be significantly down-regulated in skin fibroblasts following treatment with LGAGGAG; two of these encode the cytokines MCSF (macrophage-specific colony-stimulating factor) and TMSB10.

30 The influence of these two peptides (VVPQ and LGAGGAG) on the gene expression patterns of cultured skin fibroblasts is distinctly different. While still a preliminary study, it appears that the septapeptide LGAGGAG has a marked influence on the steady state levels of a larger

number and a greater variety of mRNAs in treated fibroblasts that the tetrapeptide VVPQ. While both peptides do influence the levels of mRNAs encoding proteins involved in DNA repair and apoptosis, LGAGGAG has a particular influence on mRNAs encoding several different cytokines known to influence the expression of genes responsible for the synthesis of elastin and several different collagen types. It is entirely possible therefore, that the mRNA level changes reflected in this array analysis represent at least part of the signaling cascade influenced by LGAGGAG. The potential signaling cascade influences induced by exposure to this septapeptide may lead to the connective tissue alterations responsible for phenotypic changes in the skin reported herein.

In contrast, the tetrapeptide VVPQ has a relatively quiescent effect (this result is limited by the 588cDNAs present in this array) on cultured skin fibroblasts. The few mRNAs that are altered in levels are almost entirely those encoding proteins involved in apoptosis and DNA repair. While apoptotic changes can have a profound influence on connective tissue remodeling, this pathway may be different from the one illustrated by the treatment with LGAGGAG which affected levels of mRNAs encoding proteins involved in cell to cell communication. The prediction from these initial results therefore, would be that these two elastin peptides have significantly different influences on the biosynthetic profiles of skin fibroblasts. Even more information could be gained about the effects of these and other elastin peptides on fibroblasts by utilizing a larger array of cDNAs. The differences in gene expression detected by these array analyses may be manifested by significant phenotypic differences on the functional integrity of the dermis and will merit further study.

TABLE VII
THE IDENTITY OF mRNAs UP-REGULATED
AS A CONSEQUENCE OF LGAGGAG TREATMENT

GENE	Ratio
cAMP-dependent protein kinase alpha-catalytic subunit (PKA C-alpha)	6

GENE	Ratio
3'5'-cAMP phosphodiesterase HPDE4A6	>10
Epithelial discoidin domain receptor 1 precursor (EDDR1; DDR1); cell adhesion kinase (CAK); TRKE; RTK6	5
colon carcinoma kinase 4 precursor (CCK4) + transmembrane receptor PTK7	5
Yamaguchi sarcoma viral-related oncogene homolog; tyrosine-protein kinase lyn	2
C-jun N-terminal kinase 3 alpha2 (JNK3A2); PRKM10 + MAP kinase p493F12	5
90-kDa heat-shock protein A (HSP90A); HSP86; HSPCA	2
protein C inhibitor (PROCI; PCI); plasma serine protease inhibitor precursor; plasminogen activator inhibitor 3	4
cAMP-dependent protein kinase type 1 beta regulatory subunit (PRKAR1B)	>30
mutL protein homolog1 (MLH1); colon cancer nonpolyposis type 2 protein (COCA2)	2
SL cytokine precursor; FMS-related tyrosine kinase 3 ligand (FLT3 ligand; FLT3LG)	>30
CD40 receptor-associated factor 1 (CRAF1)	10
X-ray repair-complementing defective repair in Chinese hamster cells 1 (XRCC1)	15
tumor necrosis factor alpha precursor (TNF-alpha; TNFA); cachectin	15
RAD23 homolog A (RAD23A; hHR23A)	>30
Activator 1 37-kDa subunit; replication factor C 37-kDa subunit (RFC37); RFC4	5

GENE	Ratio
DNA-dependent protein kinase (DNA-PK) + DNA-PK catalytic subunit (DNA-PKCS)	5
Adenosine A1 receptor (ADORA1)	>10
DNA polymerase alpha catalytic subunit (POLA)	>10
ataxia telangiectasia (ATM)	7
retinoic acid receptor epsilon (RAR-epsilon); retinoic acid receptor beta 2 (RAR-beta2; RARB); HAP	9
retinoic acid receptor beta (RXR-beta; RXRB)	25
DNA topoisomerase 1 (TOP1)	>10`
NIP1 (NIP1)	30
Caspase 10 precursor (CASP10); ICE-LIKE apoptotic protease 4 (ICE-LAP4); apoptotic protease MCH4;	22
ras associated with diabetes (RAD1)	20
Xeroderma pigmentosum group D complementing protein (XPD)	20
muscle-specific Dnase I-like precursor (Dnase1L1; DNL1L); Dnase X	10
NADH-ubiquinone dehydrogenase 1 beta subcomplex 7 18-kDa subunit (NDUFB7); complex 1-B18 (C1-B18)	7
T-cell surface glycoprotein T4/leu-3; CD4 antigen	6
CD27L antigen receptor precursor; tumor necrosis factor receptor superfamily member 7 (TNFRSF7); T14	>30
alpha1 catenin (CTNNA1); cadherin-associated protein; alpha E-catenin	>30
Fibronectin receptor beta subunit (FNRB); integrin beta 1 (ITGB1)	2

GENE	Ratio
B-lymphocyte CD19 antigen precursor; B-lymphocyte surface antigen B4; leu-12	10
Integrin alpha L (ITGAL); leukocyte adhesion glycoprotein alpha subunit precursor	5
Neurotrophin-3 precursor (NT-3); neurotrophic factor (HDNF); nerve growth factor 2 (NGF-2)	25
Ribonuclease/angiogenin inhibitor (RAI; RNH); placental ribonuclease inhibitor	6
bone morphogenetic protein 4 (BMP4) + bone morphogenetic protein 2B (BMP2B)	3
Endothelin 2 (ET2)	16
Interleukin 6 precursor (1L6); B-cell stimulatory factor 2 (BSF2)	>30
Oncostatin M (OSM)	5
Hepatocyte growth factor-like protein; macrophage-stimulating protein (MSP)	12
Placenta growth factors 1 + 2 (PLFG1 + PLGF2)	2
Angiotensin-converting enzyme (ACE)	22
Transforming growth factor-beta (TGF-beta; TGFB)	6
Teratocarcinoma-derived growth factor 1 (TDGF1); epidermal growth factor-like CRIPTO protein CR1	8
Transforming growth factor beta2 precursor (TGF-beta2; TGFB2)	6
N-sam; fibroblast growth factor receptor1 precursor (FGFR1)	15
insulin-like growth factor IA precursor (IGF1A)	15
Interleukin-13 precursor (IL-13); NC30	>10

GENE	Ratio
inhibin alpha subunit precursor (INHA)	6
acyl-CoA-binding protein (ACBP); diazepam binding inhibitor (DBI); endozepine (EP)	5
Interferon gamma precursor (IFN- gamma; IFNG); immune interferon	25
small inducible cytokine A5 (SCYA5)	3
Follistatin-related protein precursor	3
bone morphogenetic protein 2A (BMP2A)	15
Interleukin-1 beta precursor (IL-1; IL1B); catabolin	2
Hepatocyte growth factor activator (HGF activator)	3
Macrophage inflammatory protein 1 alpha precursor (MIP1-alpha); tonsillar lymphocyte LD78 alpha protein)	3

TABLE VIII
THE IDENTITY OF mRNAs DOWN-REGULATED
AS A CONSEQUENCE OF LGAGGAG TREATMENT

GENE	Ratio
mitogen-activated protein kinase p38 (MAP kinase p38)	2
60-kDa heat shock protein (HSP60); HSPD1; 60-kDa chaperonin	3
thymosin beta-10 (TMSB10; THYB10); PTMB10	2
macrophage-specific colony-stimulating factor (CSF-1; MCSF)	3

While the foregoing has been set forth in considerable detail, the sequences are presented for elucidation, and not limitation. Modifications and improvements, including equivalents, of the technology disclosed above which are within the purview and abilities of those in the art are included 5 within the scope of the claims appended hereto. It will be readily apparent to those skilled in the art that numerous modifications, alterations and changes can be made with respect to the specifics of the above description without departing from the inventive concept described herein. For example, the 10 compounds can be administered via many alternative drug delivery vehicles known in the art and the peptides can be derived from digestion of elastin or by amino acid sequencing (either solid state or liquid), as well as from over-expression in a bacterial system. Modification (either chemical or enzymatic) of the basic sequences described herein are also within the purview of the 15 present invention. For example, it appears that a reoccurring pattern in the elastin sequence is the presence of a glycine-alanine residue. Therefore the disclosed sequences may be modified to include this residue at either the amino or carboxyl ends of the peptides. The sequences may also be chemically modified to increase their activity (*e.g.*, amidation of the carboxyl 20 terminus portion of a sequence). The peptides may be chemically modified to increase their activity (*e.g.*, amidation of the carboxy terminus portion of a sequence or including a glycine or alanine residue at either end). Accordingly, all such variances should be viewed as being within the scope of the present invention as set forth in the claims below.

SEQUENCE LISTING FREE TEXT

<110> SANDBERG, LAWRENCE
 MITTS, THOMAS F.
 5 <120> ELASTIN PEPTIDE ANALOGS AND USES THEREOF
 <130> 97-489-US-P
 10 <140>
 <141>
 <150> 09/039,308
 <151> 1998-03-13
 15 <150> PCT/US99/05496
 <151> 1999-03-12
 <160> 54
 20 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 3
 25 <212> PRT
 <213> mammalian
 <400> 1
 Ala Val Gly
 30 1
 <210> 2
 <211> 4
 35 <212> PRT
 <213> mammalian
 <400> 2
 Val Gly Ala Gly
 40 1
 <210> 3
 <211> 3
 45 <212> PRT
 <213> mammalian
 <400> 3
 Ile Gly Gly
 50 1
 <210> 4
 <211> 2

	<212> PRT
	<213> mammalian
5	<400> 4 Leu Gly 1
10	<210> 5 <211> 4 <212> PRT <213> mammalian
15	<400> 5 Ile Gly Ala Gly 1
20	<210> 6 <211> 3 <212> PRT <213> mammalian
25	<400> 6 Leu Gly Gly 1
30	<210> 7 <211> 4 <212> PRT <213> mammalian
35	<400> 7 Val Ala Pro Gly 1
40	<210> 8 <211> 4 <212> PRT <213> mammalian
45	<400> 8 Leu Gly Pro Gly 1
50	<210> 9 <211> 4 <212> PRT <213> mammalian
	<400> 9

Leu Gly Ala Gly
1

5 <210> 10
<211> 4
<212> PRT
<213> mammalian

10 <400> 10
Val Gly Pro Gly
1

15 <210> 11
<211> 4
<212> PRT
<213> mammalian

20 <400> 11
Phe Gly Pro Gly
1

25 <210> 12
<211> 4
<212> PRT
<213> mammalian

30 <400> 12
Val Gly Pro Gln
1

35 <210> 13
<211> 3
<212> PRT
<213> mammalian

40 <400> 13
Leu Gly Ala
1

45 <210> 14
<211> 4
<212> PRT
<213> mammalian

50 <400> 14
Val Gly Pro Ala
1

<210> 15
 <211> 4
 <212> PRT
 <213> mammalian
 5
 <400> 15
 Val Val Pro Gly
 1
 10
 <210> 16
 <211> 4
 <212> PRT
 <213> mammalian
 15
 <400> 16
 Ala Val Pro Gly
 1
 20
 <210> 17
 <211> 4
 <212> PRT
 <213> mammalian
 25
 <400> 17
 Val Val Pro Gln
 1
 30
 <210> 18
 <211> 6
 <212> PRT
 <213> mammalian
 35
 <400> 18
 Val Ala Ala Arg Pro Gly
 1 5
 40
 <210> 19
 <211> 7
 <212> PRT
 <213> mammalian
 45
 <400> 19
 Leu Gly Ala Gly Gly Ala Gly
 1 5
 50
 <210> 20
 <211> 4
 <212> PRT
 <213> mammalian

5 <400> 20
 Ala Ile Pro Gly
 1

 10 <210> 21
 <211> 5
 <212> PRT
 <213> mammalian

 15 <400> 21
 Leu Gly Pro Gly Gly
 1 5

 20 <210> 22
 <211> 5
 <212> PRT
 <213> mammalian

 25 <400> 22
 Ala Ala Ala Gln Ala
 1 5

 30 <210> 23
 <211> 5
 <212> PRT
 <213> mammalian

 35 <400> 23
 Val Gly Val Xaa Gly
 1 5

 40 <210> 24
 <211> 5
 <212> PRT
 <213> mammalian

 45 <400> 24
 Val Tyr Pro Gly Gly
 1 5

 50 <210> 25
 <211> 6
 <212> PRT
 <213> mammalian

 <400> 25
 Ile Gly Gly Val Gly Gly
 1 5

5 <210> 26
 <211> 6
 <212> PRT
 <213> mammalian

10 <400> 26
 Val Ala Pro Gly Val Gly
 1 5

15 <210> 27
 <211> 5
 <212> PRT
 <213> mammalian

20 <400> 27
 Leu Gly Val Gly Gly
 1 5

25 <210> 28
 <211> 4
 <212> PRT
 <213> mammalian

30 <400> 28
 Leu Val Pro Gly
 1

35 <210> 29
 <211> 5
 <212> PRT
 <213> mammalian

40 <400> 29
 Phe Arg Ala Ala Ala
 1 5

45 <210> 30
 <211> 6
 <212> PRT
 <213> mammalian

50 <400> 30
 Val Gly Gly Val Pro Gly
 1 5

<210> 31
 <211> 5

<212> PRT
 <213> mammalian

 <400> 31
 5 Phe Gly Pro Gly Gly
 1 5

 10 <210> 32
 <211> 5
 <212> PRT
 <213> mammalian

 15 <400> 32
 Val Gly Val Pro Gly
 1 5

 20 <210> 33
 <211> 6
 <212> PRT
 <213> mammalian

 25 <400> 33
 Val Leu Pro Gly Ala Gly
 1 5

 30 <210> 34
 <211> 5
 <212> PRT
 <213> mammalian

 35 <400> 34
 Val Gly Leu Xaa Gly
 1 5

 40 <210> 35
 <211> 5
 <212> PRT
 <213> mammalian

 45 <400> 35
 Leu Gly Val Gly Ala
 1 5

 50 <210> 36
 <211> 4
 <212> PRT
 <213> mammalian

 <400> 36

- Ala Phe Pro Gly
1
- 5 <210> 37
<211> 5
<212> PRT
<213> mammalian
- 10 <400> 37
Ala Phe Pro Gly Ala
1 5
- 15 <210> 38
<211> 5
<212> PRT
<213> mammalian
- 20 <400> 38
Val Gly Ile Pro Ala
1 5
- 25 <210> 39
<211> 6
<212> PRT
<213> mammalian
- 30 <400> 39
Val Gly Gly Ile Pro Thr
1 5
- 35 <210> 40
<211> 7
<212> PRT
<213> mammalian
- 40 <400> 40
Val Gly Val Gly Val Pro Gly
1 5
- 45 <210> 41
<211> 6
<212> PRT
<213> mammalian
- 50 <400> 41
Leu Gly Pro Gly Val Gly
1 5

<210> 42
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 5
 <220>
 <221> MOD_RES
 <222> (1)
 <223> ACETYLTATION
 10
 <220>
 <223> Description of Artificial Sequence: peptide
 <400> 42
 15 Val Val Pro Gln
 1
 <210> 43
 20 <211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 25 <223> Description of Artificial Sequence: peptide
 <220>
 <221> MOD_RES
 <222> (1)
 30 <223> ACETYLTATION
 <400> 43
 Val Val Pro Gln
 1
 35
 <210> 44
 <211> 6
 <212> PRT
 40 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: peptide
 45 <220>
 <221> MOD_RES
 <222> (1)
 <223> ACETYLTATION
 50 <400> 44
 Gly Ala Val Val Pro Gln
 1 5

<210> 45
 <211> 5
 <212> PRT
 <213> Artificial Sequence
 5
 <220>
 <223> Description of Artificial Sequence: peptide

 <220>
 10 <221> PEPTIDE
 <222> (1)..(5)

 <400> 45
 Ala Val Val Pro Gln
 15 1 5

 <210> 46
 <211> 6
 20 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: peptide
 25
 <400> 46
 Gly Ala Val Val Pro Gln
 1 5

 30 <210> 47
 <211> 5
 <212> PRT
 <213> Artificial Sequence
 35
 <220>
 <223> Description of Artificial Sequence: peptide

 <220>
 40 <221> MOD_RES
 <222> (5)
 <223> AMIDATION

 <400> 47
 45 Ala Val Val Pro Gln
 1 5

 <210> 48
 50 <211> 6
 <212> PRT
 <213> Artificial Sequence

 <220>

<221> MOD_RES
 <222> (6)
 <223> AMIDATION

5 <220>
 <223> Description of Artificial Sequence: peptide

<400> 48
 Gly Ala Val Val Pro Gln
 10 1 5

<210> 49
 <211> 6
 15 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: peptide
 20

<220>
 <221> DISULFID
 <222> (1)..(6)
 <223> TERMINAL CYSTEINES FORM DISULFIDE BOND
 25

<400> 49
 Cys Val Val Pro Gln Cys
 1 5

30 <210> 50
 <211> 7
 <212> PRT
 <213> Artificial Sequence

35 <220>
 <223> Description of Artificial Sequence: peptide

<220>
 40 <221> DISULFID
 <222> (1)..(7)
 <223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 50
 45 Cys Ala Val Val Pro Gln Cys
 1 5

50 <210> 51
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> DISULFID

5 <222> (1)..(8)

<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 51

10 Cys Gly Ala Val Val Pro Gln Cys
1 5

<210> 52

<211> 6

15 <212> PRT

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: peptide

<220>

<221> METAL

<222> (1)..(5)

25 <223> METAL IS COPPER; BINDING TO LOCATION 1 AND 5

<400> 52

Cys Val Val Pro Gln Cys
1 5

30

<210> 53

<211> 7

<212> PRT

35 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

40 <221> METAL

<222> (1)..(7)

<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 7

<400> 53

45 Cys Ala Val Val Pro Gln Cys
1 5

<210> 54

50 <211> 8

<212> PRT

<213> Artificial Sequence

<220>

$\langle 220 \rangle$

5

<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 8

10

1

5

WHAT IS CLAIMED IS:

1. A composition useful in treating a condition of mammalian tissue, said composition being comprised of a peptide or biological equivalent thereof, selected from the group consisting of SEQ ID 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, SEQ ID 5, SEQ ID 6, SEQ ID 7, SEQ ID 8, SEQ ID 9, SEQ ID 10, SEQ ID 11, SEQ ID 12, SEQ ID 13, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 24, SEQ ID 25, SEQ ID 26, SEQ ID 27, SEQ ID 28, SEQ ID 29, SEQ ID 30, SEQ ID 31, SEQ ID 32, SEQ ID 33, SEQ ID 34, SEQ ID 35, SEQ ID 36, SEQ ID 37, SEQ ID 38, SEQ ID 39, SEQ ID 40, SEQ ID 41, SEQ ID 42, SEQ ID 43, SEQ ID 44, SEQ ID 45, SEQ ID 46, SEQ ID 47, SEQ ID 48, SEQ ID 49, SEQ ID 50, SEQ ID 51, SEQ ID 52, SEQ ID 53, and SEQ ID 54.
2. The composition of claim 1, wherein said peptide is at a therapeutically effective concentration in a range of about .0002% to about 90%.
3. The composition of claim 1, wherein said composition is a cosmetic preparation.
4. The composition of claim 3, wherein said cosmetic preparation is formulated as a topical preparation to be applied to a patient's skin.
5. The composition of claim 4, wherein said topical preparation is selected from the group consisting of an emulsion, lotion, spray, aerosol, powder, ointment, cream and foam.
6. The composition of claim 1, wherein the mammalian tissue being treated is a blood vessel.
7. The composition of claim 1, wherein the composition is useful for treating a condition selected from the group consisting of hypertension, coronary heart disease, arteriosclerosis, angina, coronary thrombosis, chronic obstructive pulmonary disease, and restenosis post angioplasty.

8. The composition of claim 1, wherein said peptide is useful in improving tissue turgor.

9. The composition of claim 1, wherein said composition further includes a pharmaceutical delivery system.

5 10. The composition of claim 9, wherein said pharmaceutical delivery system is selected from the group consisting of a topical delivery system and a subcutaneous delivery system.

11. The composition of claim 10, wherein said topical delivery system is selected from the group consisting of a cosmetic preparation,
10 powder, emulsion, lotion, spray, ointment, aerosol, cream and foam.

12. A peptide having a formula of R_1 -Valyl-Valyl-Prolyl- R_2 , wherein R_1 is an amino portion modified to include an amine, amide, or amino acid sequence having 1-10 amino acids and R_2 is a carboxy portion modified to include an amide, ester, or carboxy terminus sequence having 1-
15 10 amino acids.

13. The peptide of claim 12, wherein the peptide is selected from the group consisting of SEQ ID 15, SEQ ID 42, SEQ ID 43, SEQ ID 44, SEQ ID 45, SEQ ID 46, SEQ ID 47, SEQ ID 48, SEQ ID 49, SEQ ID 50, SEQ ID 51, SEQ ID 52, SEQ ID 53, and SEQ ID 54.

20 14. The peptide of claim 12, wherein R_2 is selected from the group consisting of a glutamine residue and modified glutamine residue.

15. A method of enhancing tissue elasticity, said method being comprised of administering a therapeutically effective concentration of a peptide selected from the group consisting of SEQ ID 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, SEQ ID 5, SEQ ID 6, SEQ ID 7, SEQ ID 8, SEQ ID 9, SEQ ID 10, SEQ ID 11, SEQ ID 12, SEQ ID 13, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 24, SEQ ID 25, SEQ ID 26, SEQ ID 27, SEQ ID 28, SEQ ID 29, SEQ ID 30, SEQ ID 31, SEQ ID 32, SEQ ID 33, SEQ ID 34, SEQ ID 35, SEQ ID 36, SEQ ID 37, SEQ ID 38, SEQ ID 39, SEQ ID 40, SEQ ID 41, SEQ ID 42,

SEQ ID 43, SEQ ID 44, SEQ ID 45, SEQ ID 46, SEQ ID 47, SEQ ID 48, SEQ ID 49, SEQ ID 50, SEQ ID 51, SEQ ID 52, SEQ ID 53, and SEQ ID 54.

16. The method of claim 15, wherein said peptide is selected from the group consisting of SEQ ID 15, SEQ ID 42, SEQ ID 43, SEQ ID 44, SEQ ID 45,
5 SEQ ID 46, SEQ ID 47, SEQ ID 48, SEQ ID 49, SEQ ID 50, SEQ ID 51, SEQ ID 52, SEQ ID 53, and SEQ ID 54.

17. The method of claim 15, wherein the tissue is selected from the group consisting of a blood vessel, lung tissue, and skin.

18. The method of claim 15, wherein the step of
10 administering the peptide is repeated over a predetermined time period.

19. A pharmaceutical composition comprised of a peptide or biological equivalent thereof, selected from the group consisting of SEQ ID 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, SEQ ID 5, SEQ ID 6, SEQ ID 7, SEQ ID 8, SEQ ID 9, SEQ ID 10, SEQ ID 11, SEQ ID 12, SEQ ID 13, SEQ ID 14, SEQ ID 15, SEQ ID 16,
15 SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 24, SEQ ID 25, SEQ ID 26, SEQ ID 27, SEQ ID 28, SEQ ID 29, SEQ ID 30, SEQ ID 31, SEQ ID 32, SEQ ID 33, SEQ ID 34, SEQ ID 35, SEQ ID 36, SEQ ID 37, SEQ ID 38, SEQ ID 39, SEQ ID 40, SEQ ID 41, SEQ ID 42, SEQ ID 43, SEQ ID 44, SEQ ID 45, SEQ ID 46, SEQ ID 47, SEQ ID 48, SEQ ID 49, SEQ ID 50, SEQ ID 51, SEQ ID 52, SEQ ID 53, and SEQ ID 54.

20. A cosmetic preparation comprised of a a peptide or biological equivalent thereof, selected from the group consisting of SEQ ID 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, SEQ ID 5, SEQ ID 6, SEQ ID 7, SEQ ID 8, SEQ ID 9, SEQ ID 10, SEQ ID 11, SEQ ID 12, SEQ ID 13, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 24, SEQ ID 25, SEQ ID 26, SEQ ID 27,
25 SEQ ID 28, SEQ ID 29, SEQ ID 30, SEQ ID 31, SEQ ID 32, SEQ ID 33, SEQ ID 34, SEQ ID 35, SEQ ID 36, SEQ ID 37, SEQ ID 38, SEQ ID 39, SEQ ID 40, SEQ ID 41, SEQ ID 42, SEQ ID 43, SEQ ID 44, SEQ ID 45, SEQ ID 46, SEQ ID 47, SEQ ID 48, SEQ ID 49, SEQ ID 50, SEQ ID 51, SEQ ID 52, SEQ ID 53, and SEQ ID 54.

ABSTRACT

The present invention is directed to a composition which is used to enhance the elasticity and/or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides or peptide-like compounds having low molecular weights and which
5 substantially correspond to sequences found in elastin. The present composition specifically includes chemical modification of the peptides described herein, specifically carboxy and amino modification including the addition of amino acids to either end of the peptide fragments.

10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212




FIG. 1




FIG. 2B




FIG. 2A




FIG. 2D



FIG. 2C


Tritiated Thymidine Incorporation with a 24 hr. Incubation of RFL-6 Cells



Synthetic Peptides (including VVPQ and Analogues of VVPQ)

Fig. 3

Tritiated Thymidine Incorporation with a 24 hr. Incubation of RFL-6 Cells



Synthetic Peptides (including VVPQ and Analogues of VVPQ)

Fig. 3

**STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER
READABLE COPY ARE THE SAME**

**I hereby state that each computer readable form submitted in this
application is the same as the "Sequence Listing" to which it is indicated to
relate.**

Date: May 30, 2000

By 

**Raymond A. Miller
Reg. No. 42,891**

**REED SMITH SHAW & MCCLAY LLP
P.O. Box 488
Pittsburgh, Pennsylvania 15230
(412) 288-4192**

Attorneys for Applicants

SEQUENCE LISTING

<110> SANDBERG, LAWRENCE
ROOS, PHILIP
MITTS, THOMAS F.

<120> USES FOR ELASTIN PEPTIDE ANALOGS

<130> 97-489-US-P

<140>

<141>

<150> 09/039,308

<151> 1998-03-13

<150> PCT/US99/05496

<151> 1999-03-12

<160> 75

<170> PatentIn Ver. 2.1

<210> 1

<211> 3

<212> PRT

<213> mammalian

<400> 1

Ala Val Gly

1

<210> 2

<211> 4

<212> PRT

<213> mammalian

<400> 2

Val Gly Ala Gly

1

<210> 3

<211> 3

<212> PRT

<213> mammalian

<400> 3
Ile Gly Gly
1

<210> 4
<211> 2
<212> PRT
<213> mammalian

<400> 4
Leu Gly
1

<210> 5
<211> 4
<212> PRT
<213> mammalian

<400> 5
Ile Gly Ala Gly
1

<210> 6
<211> 3
<212> PRT
<213> mammalian

<400> 6
Leu Gly Gly
1

<210> 7
<211> 4
<212> PRT
<213> mammalian

<400> 7
Val Ala Pro Gly
1

<210> 8
<211> 4
<212> PRT

<213> mammalian

<400> 8

Leu Gly Pro Gly

1

<210> 9

<211> 4

<212> PRT

<213> mammalian

<400> 9

Leu Gly Ala Gly

1

<210> 10

<211> 4

<212> PRT

<213> mammalian

<400> 10

Val Gly Pro Gly

1

<210> 11

<211> 4

<212> PRT

<213> mammalian

<400> 11

Phe Gly Pro Gly

1

<210> 12

<211> 4

<212> PRT

<213> mammalian

<400> 12

Val Gly Pro Gln

1

<210> 13

<211> 3
<212> PRT
<213> mammalian

<400> 13
Leu Gly Ala
1

<210> 14
<211> 4
<212> PRT
<213> mammalian

<400> 14
Val Gly Pro Ala
1

<210> 15
<211> 4
<212> PRT
<213> mammalian

<400> 15
Val Val Pro Gly
1

<210> 16
<211> 4
<212> PRT
<213> mammalian

<400> 16
Ala Val Pro Gly
1

<210> 17
<211> 4
<212> PRT
<213> mammalian

<400> 17
Val Val Pro Gln
1

<210> 18
<211> 6
<212> PRT
<213> mammalian

<400> 18
Val Ala Ala Arg Pro Gly
1 5

<210> 19
<211> 7
<212> PRT
<213> mammalian

<400> 19
Leu Gly Ala Gly Gly Ala Gly
1 5

<210> 20
<211> 4
<212> PRT
<213> mammalian

<400> 20
Ala Ile Pro Gly
1

<210> 21
<211> 5
<212> PRT
<213> mammalian

<400> 21
Leu Gly Pro Gly Gly
1 5

<210> 22
<211> 5
<212> PRT
<213> mammalian

<400> 22
Ala Ala Ala Gln Ala

1 5

<210> 23

<211> 5

<212> PRT

<213> mammalian

<400> 23

Val Gly Val Xaa Gly

1 5

<210> 24

<211> 5

<212> PRT

<213> mammalian

<400> 24

Val Tyr Pro Gly Gly

1 5

<210> 25

<211> 6

<212> PRT

<213> mammalian

<400> 25

Ile Gly Gly Val Gly Gly

1 5

<210> 26

<211> 6

<212> PRT

<213> mammalian

<400> 26

Val Ala Pro Gly Val Gly

1 5

<210> 27

<211> 5

<212> PRT

<213> mammalian

1

5

<210> 68

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> MOD_RES

<222> (8)

<223> AMIDATION

<400> 68

Leu Gly Ala Gly Gly Ala Gly Val

1

5

<210> 69

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> MOD_RES

<222> (9)

<223> AMIDATION

<400> 69

Leu Gly Ala Gly Gly Ala Gly Val Leu

1

5

<210> 70

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<400> 27

Leu Gly Val Gly Gly

1 5

<210> 28

<211> 4

<212> PRT

<213> mammalian

<400> 28

Leu Val Pro Gly

1

<210> 29

<211> 5

<212> PRT

<213> mammalian

<400> 29

Phe Arg Ala Ala Ala

1 5

<210> 30

<211> 6

<212> PRT

<213> mammalian

<400> 30

Val Gly Gly Val Pro Gly

1 5

<210> 31

<211> 5

<212> PRT

<213> mammalian

<400> 31

Phe Gly Pro Gly Gly

1 5

<210> 32

<211> 5

<212> PRT

<213> mammalian

<400> 32

Val Gly Val Pro Gly
1 5

<210> 33

<211> 6

<212> PRT

<213> mammalian

<400> 33

Val Leu Pro Gly Ala Gly
1 5

<210> 34

<211> 5

<212> PRT

<213> mammalian

<400> 34

Val Gly Leu Xaa Gly
1 5

<210> 35

<211> 5

<212> PRT

<213> mammalian

<400> 35

Leu Gly Val Gly Ala
1 5

<210> 36

<211> 4

<212> PRT

<213> mammalian

<400> 36

Ala Phe Pro Gly
1

<210> 37

<211> 5
<212> PRT
<213> mammalian

<400> 37
Ala Phe Pro Gly Ala
1 5

<210> 38
<211> 5
<212> PRT
<213> mammalian

<400> 38
Val Gly Ile Pro Ala
1 5

<210> 39
<211> 6
<212> PRT
<213> mammalian

<400> 39
Val Gly Gly Ile Pro Thr
1 5

<210> 40
<211> 7
<212> PRT
<213> mammalian

<400> 40
Val Gly Val Gly Val Pro Gly
1 5

<210> 41
<211> 6
<212> PRT
<213> mammalian

<400> 41
Leu Gly Pro Gly Val Gly
1 5

<210> 42
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> ACETYLTATION

<220>
<223> Description of Artificial Sequence: peptide

<400> 42
Val Val Pro Gln
1

<210> 43
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> MOD_RES
<222> (1)
<223> ACETYLTATION

<400> 43
Val Val Pro Gln
1

<210> 44
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> MOD_RES
<222> (1)

<223> ACETYLATION

<400> 44

Gly Ala Val Val Pro Gln

1

5

<210> 45

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> PEPTIDE

<222> (1)..(5)

<400> 45

Ala Val Val Pro Gln

1

5

<210> 46

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 46

Gly Ala Val Val Pro Gln

1

5

<210> 47

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> MOD_RES

<222> (5)

<223> AMIDATION

<400> 47

Ala Val Val Pro Gln

1 5

<210> 48

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (6)

<223> AMIDATION

<220>

<223> Description of Artificial Sequence: peptide

<400> 48

Gly Ala Val Val Pro Gln

1 5

<210> 49

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> DISULFID

<222> (1)..(6)

<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 49

Cys Val Val Pro Gln Cys

1 5

<210> 50

<211> 7

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> DISULFID
<222> (1)..(7)
<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 50
Cys Ala Val Val Pro Gln Cys
1 5

<210> 51
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> DISULFID
<222> (1)..(8)
<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 51
Cys Gly Ala Val Val Pro Gln Cys
1 5

<210> 52
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> METAL
<222> (1)..(5)
<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 5

<400> 52
Cys Val Val Pro Gln Cys
1 5

<210> 53
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> METAL
<222> (1)..(7)
<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 7

<400> 53
Cys Ala Val Val Pro Gln Cys
1 5

<210> 54
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> METAL
<222> (1)..(8)
<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 8

<400> 54
Cys Gly Ala Val Val Pro Gln Cys
1 5

<210> 55
<211> 4
<212> PRT
<213> mammalian

<400> 55
Val Val Pro Asn
1

<210> 56

<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<400> 56
Ala Val Val Pro Asn
1 5

<210> 57
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<400> 57
Gly Ala Val Val Pro Asn
1 5

<210> 58
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> MOD_RES
<222> (5)
<223> AMIDATION

<400> 58
Ala Val Val Pro Asn
1 5

<210> 59
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> MOD_RES
<222> (6)
<223> AMIDATION

<400> 59
Gly Ala Val Val Pro Asn
1 5

<210> 60
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> DISULFID
<222> (1)..(6)
<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 60
Cys Val Val Pro Asn Cys
1 5

<210> 61
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> DISULFID
<222> (1)..(7)
<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 61
Cys Ala Val Val Pro Asn Cys
1 5

<210> 62
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> DISULFID
<222> (1)..(8)
<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 62
Cys Gly Ala Val Val Pro Asn Cys
1 5

<210> 63
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> METAL
<222> (1)..(6)
<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 6

<400> 63
Cys Val Val Pro Asn Cys
1 5

<210> 64
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> METAL
<222> (1)..(7)

<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 7

<400> 64

Cys Ala Val Val Pro Asn Cys

1

5

<210> 65

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> METAL

<222> (1)..(8)

<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 8

<400> 65

Cys Gly Ala Val Val Pro Asn Cys

1

5

<210> 66

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 66

Leu Gly Ala Gly Gly Ala Gly Val

1

5

<210> 67

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<400> 67

Leu Gly Ala Gly Gly Ala Gly Val Leu

<221> DISULFID
<222> (1)..(9)
<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 70
Cys Leu Gly Ala Gly Gly Ala Gly Cys
1 5

<210> 71
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> DISULFID
<222> (1)..(10)
<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 71
Cys Leu Gly Ala Gly Gly Ala Gly Val Cys
1 5 10

<210> 72
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide

<220>
<221> DISULFID
<222> (1)..(11)
<223> TERMINAL CYSTEINES FORM DISULFIDE BOND

<400> 72
Cys Leu Gly Ala Gly Gly Ala Gly Val Leu Cys
1 5 10

<210> 73
<211> 9
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> METAL

<222> (1)..(9)

<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 9

<400> 73

Cys Leu Gly Ala Gly Gly Ala Gly Cys

1

5

<210> 74

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> METAL

<222> (1)..(10)

<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 10

<400> 74

Cys Leu Gly Ala Gly Gly Ala Gly Val Cys

1

5

10

<210> 75

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide

<220>

<221> METAL


<222> (1)..(11)

<223> METAL IS COPPER; BINDING TO LOCATION 1 AND 115

<400> 75

Cys Leu Gly Ala Gly Gly Ala Gly Val Leu Cys

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available

There are 4 drawings
3 formal
1 informal